Citi initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $34 price target The firm believes the shares warrant a premium valuation given the company’s profitability and elevated growth profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with a Buy at TD Cowen
- Caris Life Sciences initiated with an Outperform at Wolfe Research
- Strong Sales Growth and Strategic Market Expansion Drive Buy Rating for Caris Life Sciences
- Caris Life Sciences initiated with a Buy at Guggenheim
- Caris Life Sciences initiated with an Overweight at JPMorgan